Details of the Drug Combination

General Information of Drug Combination (ID: DCJ3B5G)

Drug Combination Name
JNK-IN-8 Topetecan
Indication
Disease Entry Status REF
Papillary renal cell carcinoma Investigative [1]
Component Drugs JNK-IN-8   DMLWYJB Topetecan   DMAE6LK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: ACHN
Zero Interaction Potency (ZIP) Score: 0
Bliss Independence Score: 0.04
Loewe Additivity Score: 1.54
LHighest Single Agent (HSA) Score: 2.92

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JNK-IN-8
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
JNK-IN-8 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Stress-activated protein kinase JNK3 (JNK3) TT056SO MK10_HUMAN Inhibitor [2]
JNK2 messenger RNA (JNK2 mRNA) TT3IVG2 MK09_HUMAN Inhibitor [2]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
JNK-IN-8 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cell division cycle and apoptosis regulator protein 1 (CCAR1) OTUXLQZZ CCAR1_HUMAN Increases Expression [4]
------------------------------------------------------------------------------------
Indication(s) of Topetecan
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [3]
Topetecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DC2SNYV HL-60(TB) Investigative [1]
Anaplastic large cell lymphoma DCVB2WY SR Investigative [1]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
4 A H2AX?CARP-1 Interaction Regulates Apoptosis Signaling Following DNA Damage. Cancers (Basel). 2019 Feb 14;11(2):221. doi: 10.3390/cancers11020221.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).